Oneness Biotech Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Shuling Cheng

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	3.3yrs

Actualizaciones recientes de la dirección

Recent updates

Announcing: Oneness Biotech (GTSM:4743) Stock Soared An Exciting 936% In The Last Three Years

Mar 01

CEO

Shuling Cheng

less than a year

Permanencia

Dr. Shuling Cheng, Ph. D., served as Chief Strategy Officer of Medeon Biodesign Inc. until 2020. Dr. Cheng served as Vice President of Research and Development at Medeon Biodesign, Inc. and served as its D...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Nien-Yi Chen	Deputy General Manager of Antibody New Drug Division;	no data	NT$6.03m	0.076% NT$ 38.5m
Shuling Cheng	President	less than a year	sin datos	sin datos
Ting-Fang Chen	Financial Officer & Acting Spokesperson	less than a year	sin datos	sin datos
Ai-Chia Yu	Accounting Officer	less than a year	sin datos	sin datos
Wen Ci Xiao	Accounting Supervisor	less than a year	sin datos	sin datos
Jui-Ching Chen	Director of New Drug Development Department	no data	sin datos	sin datos
Kung-Ming Lu	Director of Operation Center	no data	sin datos	sin datos
Tzu-Chun Yang	Associate General Manager of Information Technology Department	no data	NT$2.14m	sin datos

0.3yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de 4743 no se considera experimentado ( 0.3 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Yi-Fu Lin	Director	2.5yrs	sin datos	sin datos
Tu-Mu Kuo	Director	less than a year	sin datos	sin datos
Suei Lu	Independent Director	6.4yrs	NT$289.00k	sin datos
Jui-Wen Huang	Independent Director	9.4yrs	NT$289.00k	sin datos
Hsien-Shou Kuo	Chairman	14.6yrs	NT$22.00k	0.0024% NT$ 1.2m
San-Kuei Huang	Independent Director	3.3yrs	NT$181.00k	sin datos
Rey-Yuh Wu	Independent Director	3.3yrs	NT$126.00k	sin datos

3.3yrs

Permanencia media

Junta con experiencia: La junta directiva de 4743 se considera experimentada (3.3 años de antigüedad promedio).

Oneness Biotech Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Oneness Biotech Co., Ltd., Annual General Meeting, May 21, 2024

Oneness Biotech Co., Ltd., Annual General Meeting, Apr 18, 2023

Oneness Biotech Co., Ltd. Announces the By-Election of Lin, Yi-Fu as Director

Oneness Biotech Co., Ltd. Announces the By-Election of Lin, Yi-Fu as Director

Oneness Biotech Co., Ltd., Annual General Meeting, May 24, 2022

Oneness Biotech Co., Ltd., Annual General Meeting, May 21, 2021

Recent updates

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 19% to NT$234

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Oneness Biotech Co., Ltd. to Report Q2, 2024 Results on Aug 12, 2024

New major risk - Revenue and earnings growth

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Oneness Biotech Co., Ltd. Agrees to Withdraw the 510(K) for Bonvadis Chronic Wound and Resubmit After the Supplementing Animal Study Data

US FDA Agrees Oneness Biotech Co., Ltd.'s S.C. Injection Formulation of FB825 to Proceed with Phase 2 Clinical Trial to Treat Moderate-To-Severe Atopic Dermatitis

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

Oneness Biotech Co., Ltd. has filed a Follow-on Equity Offering.

Oneness Biotech Co., Ltd., Annual General Meeting, May 21, 2024

Oneness Biotech Co., Ltd. Announces Submission of A Phase II Clinical Trial Protocol Forsubcutaneous Injection Formulation of FB825 in Patientswith Moderate-To-Severe Atopic Dermatitis

Oneness Biotech Co., Ltd. Obtains Import License in Thailand from Thai Food and Drug Administration

Oneness Biotech Co., Ltd. Obtains Import License in Thailand from Thai Food and Drug Administration

Price target decreased by 14% to NT$262

Consensus revenue estimates increase by 158%

Oneness Biotech Co., Ltd. Announces Approval of FESPIXON

New minor risk - Share price stability

New minor risk - Shareholder dilution

Oneness Biotech Co., Ltd. Submits 510(k) Application to the U.S. FDA to Expand the Intended Patient Population and Add Multiple Chronic Wound Indications for Bonvadis

New minor risk - Revenue size

Second quarter 2023 earnings: EPS misses analyst expectations

New minor risk - Profitability

Price target decreased by 10% to NT$274

Oneness Biotech Co., Ltd. Announces Submission of Registration Application for Bonvadis, the Wound Care Topical Cream to the Drug Regulatory Authority of Pakistan (DRAP)

US FDA agrees to proceed with Phase 2 clinical trial for SNS812, a broad-spectrum siRNA for COVID-19 infection, co-developed by Oneness & Microbio (Shanghai)

Oneness Biotech Co., Ltd. Receives Approval from Malaysia NPRA for FESPIXON, the New Drug in Treatment of Diabetic Footulcers

Upcoming dividend of NT$0.098 per share

Oneness Biotech Co., Ltd. Announces Cash Dividend, Payable on July 21, 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Oneness Biotech Co., Ltd., Annual General Meeting, Apr 18, 2023

Third quarter 2022 earnings released

Third quarter 2022 earnings released: EPS: NT$0.71 (vs NT$0.46 loss in 3Q 2021)

Microbio (Shanghai) and Oneness Co-Develop Broad-Spectrum siRNA (SNS812) to Treat SARS-CoV-2 Infection, Greenlighted by FDA to Proceed with A Phase I Study

Oneness Biotech Co., Ltd. Submits an IND to US FDA for A Phase Iclinical Trial on the Broad-Spectrum Anti-SARS-CoV-2siRNA (SNS812) Co-Developed with Microbio (Shanghai)

Second quarter 2022 earnings released: EPS: NT$0.87 (vs NT$1.24 loss in 2Q 2021)

Oneness Biotech Co., Ltd. Announces the By-Election of Lin, Yi-Fu as Director

Oneness Biotech Co., Ltd. Announces the By-Election of Lin, Yi-Fu as Director

First quarter 2022 earnings released: EPS: NT$1.01 (vs NT$0.31 in 1Q 2021)

Oneness Biotech Co., Ltd. Announces Food and Drug Administration Philippines Accepts NDA Application of Diabetic Foot Ulcer New Drug, Fespixon

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Oneness Biotech Co., Ltd. Announces The Malaysia National Pharmaceutical Regulatory Agency Accepts NDA Application of the Diabetic Foot Ulcer New Drug, Fespixon

Oneness Biotech Co., Ltd., Annual General Meeting, May 24, 2022

Oneness Biotech Co., Ltd. Announces the Data of Sns812 Were Published by EMBO Molecular Medicine

Oneness Biotech Co., Ltd. Announces the Partial Efficacy Data for the Phase 2a Study of FB825 in the Treatment of Atopic Dermatitis in the U.S

Third quarter 2021 earnings released: NT$0.46 loss per share (vs NT$0.064 profit in 3Q 2020)

Independent Director Kun-Ta Li has left the company

Second quarter 2021 earnings released: NT$1.24 loss per share (vs NT$1.40 profit in 2Q 2020)

Oneness Biotech Co., Ltd. Announces Phase 3 International MRCT Study Results of the Diabetic Foot Ulcer New Drug

First quarter 2021 earnings released: EPS NT$0.31 (vs NT$0.54 loss in 1Q 2020)

First quarter 2021 earnings released: EPS NT$0.31 (vs NT$0.54 loss in 1Q 2020)

Oneness Notified That FB704A Is Safe to Proceed with the Phase 2 Clinical Trial in Severe Asthma Under US FDA IND

Announcing: Oneness Biotech (GTSM:4743) Stock Soared An Exciting 936% In The Last Three Years

Full year 2020 earnings released: NT$0.68 loss per share (vs NT$1.28 loss in FY 2019)

Oneness Biotech Co., Ltd. Receives the Letter from MOHW Informing that ON101 for DFUs has Obtained the New Drug Approval Andits Drug Certificate Will Be Notified for Receipt

Oneness Biotech Co., Ltd., Annual General Meeting, May 21, 2021

Oneness Submits an IND to US FDA on Phase II Clinical Trial on Severe Asthma of FB704A

Oneness Will Not Proceed with the ON101 Phase3 Clinical Trial (ON101CLCT04) Application with BfArM of Germany Based on Strategic Consideration

New 90-day low: NT$185

New 90-day low: NT$213

TFDA Notifies Oneness of Submitting Supplementary information for Rebuttal of FB704A Phase II Clinical trial Application for Severe Neutrophilic Asthma

New 90-day low: NT$260

Third quarter 2020 earnings released: EPS NT$0.06

New 90-day low: NT$265

CEO

Permanencia

Equipo directivo